Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
|
|
- Norma Mason
- 5 years ago
- Views:
Transcription
1 bs_bs_banner doi: /jog J. Obstet. Gynaecol. Res. Vol. 41, No. 2: , February 2015 Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology Wataru Yamagami and Daisuke Aoki Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan Abstract The Japan Society of Obstetrics and Gynecology collects and analyzes annual data on gynecologic cancers from member institutions. Here we present the Patient Annual Report for 2012 and the Treatment Annual Report for Data on 7028 patients with cervical cancer, 8217 with endometrial cancer, 5140 with ovarian cancer and 1725 with ovarian borderline tumor for whom treatment was initiated in 2012 were summarized in the Patient Annual Report. Data on the prognosis of 2699 patients with cervical cancer, 3243 with endometrial cancer and 1898 with ovarian cancer for whom treatment was initiated in 2006 were analyzed in the Treatment Annual Report. In the Patient Annual Report for 2012, stage I accounted for 55.4%, stage II for 23.0%, stage III for 11.0% and stage IV for 10.6% of all patients with cervical cancer. Stage I accounted for 72.2%, stage II for 7.0%, stage III for 13.4% and stage IV for 7.3% of all patients with endometrial cancer. Stage I accounted for 43.1%, stage II for 9.2%, stage III for 29.7% and stage IV for 7.2% of all patients with ovarian cancer. In the Treatment Annual Report for 2006, the 5-year overall survival rates for patients with cervical cancer were 92.9% for stage I, 74.6% for stage II, 55.3% for stage III and 24.3% for stage IV. The equivalent rates for patients with endometrial cancer were 96.3%, 92.7%, 80.6% and 35.8%, respectively; and those for patients with ovarian surface epithelial stromal tumors were 90.6%, 82.9%, 48.7% and 40.9%, respectively. Key words: annual report, cervical cancer, endometrial cancer, ovarian cancer, gynecologic cancer, Japan. Introduction The Japan Society of Obstetrics and Gynecology (JSOG) collects annual data on the clinicopathologic factors and prognosis of gynecologic cancers from member institutions every year and analyzes this information to investigate the trends in gynecologic cancers in Japan. Here we present the Patient Annual Report for 2012 and the Treatment Annual Report for The data presented in this paper are quoted and modified from previous reports. 1,2 Patients and Methods For patients whose treatment was initiated in 2012, data were collected, retrospectively analyzed and summarized in the Patient Annual Report for For patients whose treatment was initiated in 2006, data on prognosis were collected, analyzed and summarized in the Treatment Annual Report for 2006, assuming a 5-year follow-up period was necessary. This study was conducted with the approval of the ethics committee of JSOG. Patient Annual Report for 2012 The subjects included patients with cervical intraepithelial neoplasia 3 (CIN3), 7028 with stage I IV cervical cancer, 558 with atypical endometrial hyperplasia (AEH), 8217 with stage I IV endometrial cancer, 5140 with ovarian cancer and 1725 with borderline ovarian tumor. These patients were histopathologically diagnosed in one of the 346 member institutions of Received: August Accepted: August Reprint request to: Professor Daisuke Aoki, Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi Shinjuku-ku, Tokyo , Japan. aoki@z7.keio.jp 2014 The Authors 167
2 W. Yamagami and D. Aoki JSOG and were administered treatment between January and December The clinical stages of cervical cancer and surgical stages of endometrial cancer were based on the International Federation of Gynecology and Obstetrics (FIGO) 2008 staging system. The surgical stages for ovarian cancer, including borderline ovarian tumor, were based on the FIGO 1988 staging system. Data on age, clinical stage, histologic type and treatment were collected for patients with cervical cancer; data on age, surgical stage, histologic type and treatment were collected for patients with endometrial cancer; and data on age, surgical stage, histologic type and treatment were collected for patients with ovarian cancer and borderline ovarian tumor. Patient information was anonymized in a linkable fashion and registered from each institution onto the website of JSOG. Statistical analyses were performed after two or more members of the Committee on Gynecologic Oncology checked the integrity of the collected data. Treatment Annual Report for 2006 In all, 199 institutions provided data on the 3-year and 5-year prognoses of patients registered in any of the member institutions of JSOG between January and December 2006 and those reported in the Patient Annual Report for These patients included 4750 with cervical cancer, 4631 with endometrial cancer and 3204 with ovarian cancer. The clinical stages of cervical cancer and surgical stages of endometrial cancer and ovarian cancer, including borderline ovarian tumor, were based on the FIGO 1988 staging system. Data from institutions in which 20% of registered patients were untraceable were not included in the analysis of treatment outcomes and prognoses because such data would decrease the reliability of treatment outcomes and prognoses. Accordingly, data of 2699 patients with cervical cancer, 3243 with endometrial cancer and 2002 with ovarian cancer were ultimately included in the outcome analysis. Personal information was anonymized in a linkable fashion and information on prognoses was then registered on the JSOG website. Thereafter, the data were statistically analyzed at the Biostatistics Center, Kurume University. Statistical analysis The overall survival rates were analyzed by the Kaplan Meier method and statistical significance was determined using the log rank test. Results Patient Annual Report for 2012 Cervical cancer Age distribution (Fig. 1). Patients aged 40 49, and years accounted for 25.5%, 19.4% and 18.5% of all registered patients, respectively; these findings demonstrated that the disease predominantly affected women in their 40s. Stages (Fig. 2). Stage I accounted for 55.4% (stage IA1, 14.2%; stage IA2, 1.7%; stage IB1, 29.6%; stage IB2, 7.6%; subclassification unknown, 2.4%), stage II accounted for 23.0% (stage IIA1, 3.1%; stage IIA2, 2.5%; stage IIB, 16.8%; subclassification unknown, 0.7%), stage III accounted for 11.0% (stage IIIA, 1.1%; stage IIIB, 9.8%; subclassification unknown, 0.1%) and stage IV accounted for 10.6% (stage IVA, 3.0%; stage IVB, 7.6%; subclassification unknown, 0.0%) of all patients. Histologic types (Table 1). Squamous cell carcinoma was the most commonly encountered histopathologic type, Figure 1 Age distribution by clinical stage for patients with stage I IV cervical cancer in 2012., Stage I;, Stage II;, Stage III;, Stage IV The Authors
3 Annual report of JSOG Figure 2 Distribution of clinical stages for patients with cervical cancer in *Subclassification unknown. Table 1 Histologic types of cervical cancer in 2012 Histologic type Number % Squamous cell carcinoma, classification unknown Squamous cell carcinoma, keratinizing type Squamous cell carcinoma, non-keratinizing type Basaloid carcinoma Verrucous carcinoma Condylomatous carcinoma Papillary squamous cell carcinoma Lymphoepithelioma-like squamous cell carcinoma Squamotransitional carcinoma Microinvasive squamous cell carcinoma Adenocarcinoma, classification unknown Mucinous adenocarcinoma, endocervical type Mucinous adenocarcinoma, intestinal type Endometrioid adenocarcinoma Clear cell adenocarcinoma Serous adenocarcinoma Mesonephric adenocarcinoma Mucinous adenocarcinoma, minimal-deviation type Mucinous adenocarcinoma, villoglandular type Microinvasive adenocarcinoma Adenosquamous carcinoma Glassy cell carcinoma Adenoid cystic carcinoma Adenoid basal carcinoma Carcinoid Atypical carcinoid Small cell carcinoma Large cell neuroendocrine carcinoma Undifferentiated carcinoma Carcinosarcoma Others Unknown Total The Authors 169
4 W. Yamagami and D. Aoki Figure 3 Distribution of treatment methods by clinical stage for patients with cervical cancer in 2012., Stage I;, Stage II;, Stage III;, Stage IV. Figure 4 Age distribution by surgical stage for patients with stage I IV endometrial cancer in 2012., Stage I;, Stage II;, Stage III;, Stage IV. accounting for 73.5% of all patients, while adenocarcinoma accounted for 23.4% of all patients. The other rare histologic types encountered are shown in Table 1. Treatment (Fig. 3). Of the patients, 38.1% underwent just surgery, 20.7% received chemotherapy and other therapies in addition to radiotherapy, 12.6% received chemotherapy and other therapies in addition to surgery, 12.1% received just radiotherapy and 4.8% received radiotherapy in addition to surgery. Other therapies shown in the figure include immunotherapy and hormone therapy. Endometrial cancer Age distribution (Fig. 4). Patients aged 50 59, and years accounted for 30.3%, 27.8% and 15.8%, respectively, of all patients; these findings showed that the disease predominantly affected women in their 50s. On the other hand, patients aged <40 years accounted for just 5.3% of all patients. Surgical stages (Fig. 5). Stage I accounted for 72.2% (stage IA, 54.3%; stage IB, 17.4%; subclassification unknown, 0.5%), stage II accounted for 7.0%, stage III accounted for 13.4% (stage IIIA, 4.3%; stage IIIB, 0.9%; stage IIIC1, 4.2%; stage IIIC2, 3.3%; subclassification unknown, 0.7%) and stage IV accounted for 7.3% (stage IVA, 0.3%; stage IVB, 6.9%; subclassification unknown, 0.1%) of all patients. Histologic types (Table 2). Endometrioid carcinoma was the most common, accounting for 82.3% of all tumors. Other histologic types included serous adenocarcinoma (5.0%), clear cell adenocarcinoma (2.1%) and mixed carcinoma (2.4%). Carcinosarcoma was observed in 4.9% of patients. Treatment (Fig. 6). Of the patients, 56.4% underwent just surgery, 37.9% received chemotherapy and other therapies, such as hormone therapy, after surgery and 0.9% received radiotherapy after surgery. Other therapies shown in the figure include immunotherapy. Ovarian cancer Age distribution (Fig. 7). Patients aged 60 69, and years accounted for 27.9%, 26.1% and 19.2%, The Authors
5 Annual report of JSOG Figure 5 Distribution of surgical stages for patients with endometrial cancer in *Subclassification unknown. Figure 6 Distribution of treatment methods by surgical stage for patients with endometrial cancer in 2012., Stage I;, Stage II;, Stage III;, Stage IV. Table 2 Histologic types of endometrial cancer in 2012 Histologic type No. of % patients Endometrioid adenocarcinoma Endometrioid adenocarcinoma with squamous differentiation Endometrioid adenocarcinoma, villoglandular variant 4 0 Endometrioid adenocarcinoma, secretory variant 2 0 Serous adenocarcinoma Clear cell adenocarcinoma Mucinous adenocarcinoma Squamous cell carcinoma Mixed carcinoma Transitional cell carcinoma 0 0 Small cell carcinoma Undifferentiated carcinoma Carcinofibroma 1 0 Carcinosarcoma Classification unknown Total The Authors 171
6 W. Yamagami and D. Aoki Figure 7 Age distribution by surgical stage for patients with ovarian cancer in 2012., Stage I;, Stage II;, Stage III;, Stage IV;, Unknown;, Neoadjuvant chemotherapy. Figure 8 Distribution of surgical stages in patients with ovarian cancer and borderline ovarian tumor in 2012., Ovarian cancer;, Ovarian borderline tumor. respectively, of all patients; this indicated that the disease predominantly affected women in their 50s and 60s. Surgical stages (Fig. 8). Stage I accounted for 43.1% (stage Ia, 16.4%; stage Ib, 1.0%; stage Ic, 25.7%), stage II accounted for 9.2% (stage IIa, 1.2%; stage IIb, 1.3%; stage IIc, 6.7%), stage III accounted for 29.7% (stage IIIa, 1.3%; stage IIIb, 4.2%; stage IIIc, 24.2%) and stage IV accounted for 7.2% of all patients. Neoadjuvant chemotherapy was administered to 10.7% of patients. Histologic types (Table 3). Surface epithelial stromal tumors accounted for 95.2%, serous adenocarcinoma for 35.4%, clear cell adenocarcinoma for 23.8%, endometrioid adenocarcinoma for 16.9% and mucinous adenocarcinoma for 10.9% of all tumors. Sex cord stromal and germ cell tumors were observed in 0.2% and 3.3% of patients, respectively. Treatment (Fig. 9). Of the patients, 79.7% received chemotherapy after surgery, 18.2% underwent just surgery and 1.4% received just chemotherapy. Borderline ovarian tumor Surgical stages (Fig. 8). Stage I accounted for 93.2% (stage Ia, 65.6%; stage Ib, 2.6%; stage Ic, 25.1%), stage II accounted for 1.9% (stage IIa, 0.2%; stage IIb, 0.6%; stage IIc, 1.0%), stage III accounted for 3.7% (stage IIIa, 0.5%; stage IIIb, 1.0%; stage IIIc, 2.1%) and stage IV accounted for 0.5% of patients. Neoadjuvant chemotherapy was administered to 0.6% of patients. Histologic types (Table 4). Mucinous tumors accounted for 55.7%, serous tumors for 21.2%, endometrioid tumors for 2.1% and mixed tumors for 3.0% of all tumors. In addition, granulosa cell tumors accounted for 8.3% and immature teratomas (G1, G2) for 4.0% of tumors The Authors
7 Annual report of JSOG Table 3 Histologic types of ovarian cancer in 2012 Histologic type No. of % patients Serous adenocarcinoma Mucinous adenocarcinoma Endometrioid adenocarcinoma Clear cell adenocarcinoma Undifferentiated carcinoma Mixed-type adenocarcinoma Others: adenosarcoma (homologous) Others: adenosarcoma (heterologous) Others: mesodermal mixed tumor (homologous) Others: mesodermal mixed tumor (heterologous) Others: stromal sarcoma Others: malignant Brenner tumor Others: transitional cell carcinoma Others: unclassifiable Others: others Sertoli-stromal cell tumor (poorly differentiated) Others: fibrosarcoma Others: others Immature teratoma G Dysgerminoma Yolk sac tumor Malignant mixed germ cell tumor Malignant mixed germ cell tumor: yolk sac tumor + dysgerminoma Malignant mixed germ cell tumor: yolk sac tumor + immature teratoma Malignant mixed germ cell tumor: others Mature cystic teratoma with malignant transformation Others: embryonal carcinoma Others: polyembryoma Others: choriocarcinoma Others: others Sarcoma Others: carcinoma of the rete ovarii Others: small cell carcinoma Others: hepatoid carcinoma Others: squamous cell carcinoma Others: gestational choriocarcinoma Others: malignant lymphoma (primary) Others: unclassifiable Others: tumor possibly originating from the Wolffian duct Others: others Total 5140 Treatment (Fig. 10). Of the patients, 92.8% underwent just surgery and 7.2% received chemotherapy after surgery. Treatment Annual Report for 2006 Cervical cancer Overall survival by clinical stage (Fig. 11). The overall survival (OS) rates by clinical stage are shown in Figure 11. The 5-year OS rates were 92.9% for stage I (stage Ia1, 99.0%; stage Ia2, 100%; stage Ib1, 93.3%; stage Ib2, 80.0%), 74.6% for stage II (stage IIa, 81.4%; stage IIb, 71.9%), 55.3% for stage III (stage IIIa, 53.4%; stage IIIb, 55.5%) and 24.3% for stage IV patients (stage IVa, 27.9%; stage IVb, 21.8%). There were significant differences in OS between stages I and II (P < ), stages II and III (P < ) and stages III and IV (P = ). OS by histologic type (Fig. 12). The OS rates by histologic type are shown in Figure 12. The 5-year OS rates were 78.1%, 76.9%, 78.9% and 53.9% in patients with squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma and other cancers, respectively The Authors 173
8 W. Yamagami and D. Aoki Figure 9 Distribution of treatment methods by surgical stage for patients with ovarian cancer in 2012., Stage I;, Stage II;, Stage III;, Stage IV;, Unknown;, Neoadjuvant chemotherapy. Table 4 Histologic types of ovarian borderline tumor in 2012 Histologic type No. of % patients Serous tumor Mucinous tumor Others: endometrioid tumor Others: clear cell tumor Others: proliferating Brenner tumor Others: mixed tumor 52 3 Others: unclassifiable Others: others Granulosa cell tumor Sertoli-stromal cell tumor (moderately differentiated) Others: gynandroblastoma 0 0 Others: steroid cell tumor (unclassifiable) Others: others Immature teratoma (G1, G2) 69 4 Others: carcinoid Others: neuroectodermal tumor Others: others Tumor of borderline malignancy other than the above: 0 0 gonadoblastoma Tumor of borderline malignancy other than the above: mixed germ cell sex cord-stromal tumor Tumor of borderline malignancy other than the above: others 0 0 Total 1725 Patients with other cancers had a significantly worse prognosis compared with those with squamous cell carcinoma (P = ), adenocarcinoma (P = ) and adenosquamous carcinoma (P = ). Endometrial cancer OS by surgical stage (Fig. 13). The OS rates by surgical stage are shown in Figure 13. The 5-year OS rates were 96.3% for stage I patients (stage Ia, 98.8%; stage Ib, 96.6%; stage Ic, 92.3%), 92.7% for stage II patients (stage IIa, 92.9%; stage IIb, 93.2%), 80.6% for stage III patients (stage IIIa, 85.9%; stage IIIb, 54.5%; stage IIIc, 75.1%) and 35.8% for stage IV patients (stage IVa, 57.0%; stage IVb, 34.1%). There were significant differences between patients with stages I and II (P < ), stages II and III (P < ) and stages III and IV (P < ). OS by histologic type (Table 5). The 5-year OS rates were 96.8%, 89.9% and 80.0% for patients with G1, G2 and G3 endometrioid adenocarcinoma, respectively. Comparison of survival among stages revealed 5-year OS The Authors
9 Annual report of JSOG Figure 10 Distribution of treatment methods by surgical stage for patients with borderline ovarian tumor in 2012.,Stage I;, Stage II;, Stage III;, Stage IV;, Unknown;, Neoadjuvant chemotherapy. Figure 11 Overall survival in patients with stage I IV cervical cancer by clinical stage in Log rank P < , International Federation of Gynecology and Obstetrics (FIGO) stage I;, FIGO stage II;, FIGO stage III;, FIGO stage IV. Figure 13 Overall survival by surgical stage for patients with stage I IV endometrial cancer in Log rank P < , International Federation of Gynecology and Obstetrics (FIGO) stage I;, FIGO stage II;, FIGO stage III;, FIGO stage IV. Figure 12 Overall survival by histologic type for patients with stage I IV cervical cancer in Log rank P < , Squamous cell carcinoma;, Adenocarcinoma;, Adenosquamous carcinoma;, Others. rates of 96.9%, 90.1% and 93.6% for patients with stage I endometrioid carcinoma, serous/mucinous/clear adenocarcinoma and other histologic types, respectively, and 93.6%, 84.2% and 92.4% for patients with stage II endometrioid carcinoma, serous/mucinous/ clear adenocarcinoma and other histologic types, respectively. For patients with stage III endometrioid carcinoma, serous/mucinous/clear adenocarcinoma and other histologic types, the rates were 86.7%, 60.8% and 70.1%, respectively, while the 5-year OS rates were 45.6%, 14.2% and 25.7% for stage IV endometrioid carcinoma, serous/mucinous/clear adenocarcinoma and other histologic types, respectively. Ovarian cancer OS by surgical stage (Fig. 14). The OS rates by surgical stage are shown in Figure 14. When compared among 2014 The Authors 175
10 W. Yamagami and D. Aoki Table 5 Five-year survival rates of endometrial cancer patients by stage and histologic type FIGO stage Histology Patients treated 5-year survival No. % % I Endometrioid adenocarcinoma Serous, mucinous, clear cell adenocarcinoma Others II Endometrioid adenocarcinoma Serous, mucinous, clear cell adenocarcinoma Others III Endometrioid adenocarcinoma Serous, mucinous, clear cell adenocarcinoma Others IV Endometrioid adenocarcinoma Serous, mucinous, clear cell adenocarcinoma Others FIGO, International Federation of Gynecology and Obstetrics. Figure 14 Overall survival by surgical stage for patients with ovarian cancer in Log rank P < , International Federation of Gynecology and Obstetrics (FIGO) stage I;, FIGO stage II;, FIGO stage III;, FIGO stage IV. the stages of surface epithelial stromal tumors, the 5-year OS rates were 90.6% in stage I patients (stage Ia, 93.8%; stage Ib, 78.3%; stage Ic(b), 91.2%; stage Ic(1), 81.0%; stage Ic(2), 86.7%; stage Ic(a), 87.5%), 82.9% in stage II patients (stage IIa, 100%; stage IIb, 80.8%; stage IIc(b), 80.1%; stage IIc(1), 81.8%; stage IIc(2), 80.3%; stage IIc(a), 84.0%), 48.7% in stage III patients (stage IIIa, 65.2%; stage IIIb, 56.7%; stage IIIc, 47.0%) and 40.9% in stage IV patients. There were significant differences in OS between stages I and II (P < ), stages II and III (P < ) and stages III and IV (P < ). The above analysis did not include patients who received neoadjuvant chemotherapy; the 5-year OS rate of patients who received neoadjuvant chemotherapy was 40.3%. Figure 15 Overall survival by histologic type for patients with ovarian cancer in Log rank P < , Serous;, Mucinous;, Endometrioid;, Clear;, Other. OS by histologic type (Fig. 15). The OS rates by histologic type are shown in Figure 15. Patients with serous adenocarcinoma had a significantly poorer prognosis compared with those with mucinous adenocarcinoma (P < ), endometrioid adenocarcinoma (P < ) and clear cell adenocarcinoma (P < ). Discussion In this analysis, the number of patients with cervical cancer, endometrial cancer, ovarian cancer and borderline ovarian tumor had increased from the analysis of This increase was not only influenced by the increase in patients with gynecologic cancer in Japan but also by the increase in the number of member institutions in JSOG (305 institutions in institutions in 2012) The Authors
11 Annual report of JSOG For the Patient Annual Report in 2012, the FIGO 2008 staging classification was adopted for the statistical analysis of cervical and endometrial cancers, while the FIGO 1988 staging classification was adopted for the statistical analysis of ovarian cancer. Carcinoma in situ, which was previously defined as stage 0 cervical cancer, was excluded from this analysis. This classification was included with severe dysplasia as CIN3. Therefore, the population of CIN3 did increase from AEH that was previously defined as stage 0 endometrial cancer was also excluded from this analysis. The number of patients with stage I endometrial cancer had increased, while that of patients with stage III endometrial cancer had decreased. These findings were influenced by the modification that patients with positive peritoneal cytology were not classed as stage IIIA in the FIGO 2008 staging system. On the other hand, there were no significant differences from 2011 in the number of ovarian cancers and borderline ovarian tumors. For the treatment annual reports for 2006, the FIGO 1988 staging classification was adopted for this statistical analysis of cervical, endometrial and ovarian cancers. Prognosis was analyzed by the Kaplan Meier method. As in the previous report, 3 information from institutions where prognoses were untraceable for 20% of patients was excluded from the analysis in the present study. Among patients with a known prognosis, 56.8% with cervical cancer, 70.0% with endometrial cancer and 62.5% with ovarian cancer were included in the analysis of prognosis. However, it may be possible that this selection of cases was influenced by a selection bias and that prognoses appeared better than they actually were in this study. In particular, the prognosis of stage IV cervical cancer and stage IV endometrial cancer may be susceptible to some bias because the number of cases was limited. Therefore, a worse prognosis for stage IV cervical cancer and a better prognosis for stage IV endometrial cancer may have been observed in 2012 compared with those in Conclusions We thus presented the Patient Annual Report and Treatment Annual Report on gynecologic tumors (cervical, endometrial and ovarian cancers and borderline ovarian tumor) in Japan. Acknowledgment The authors thank the member institutions of the Japan Society of Obstetrics and Gynecology for their cooperation in providing data on patients with gynecologic tumors. The authors also thank all members of the Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology, Dr Hidetaka Katabuchi, Dr Hidenori Kato, Dr Toshiaki Saito, Dr Toru Sugiyama, Dr Nao Suzuki, Dr Toru Hachisuga and Dr Yoichi Aoki for their contribution in summarizing the data and Ms Miyuki Nakai for her secretarial help. The authors thank the Biostatistics Center, Kurume University for data analysis. Disclosure There are no conflicts of interest to declare. References 1. Aoki D. The patient annual report in Acta Obstet Gynaecol Jpn 2014; 66: Aoki D. The treatment annual report in Acta Obstet Gynaecol Jpn 2014; 66: Aoki D. Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, J Obstet Gynaecol Res 2014; 40: The Authors 177
Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013
bs_bs_banner doi:10.1111/jog.12360 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 338 348, February 2014 Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 Daisuke
More informationClinical statistics of gynecologic cancers in Japan
J Gynecol Oncol. 2017 Mar;28(2):e32 pissn 2005-0380 eissn 2005-0399 Review Article Clinical statistics of gynecologic cancers in Japan Wataru Yamagami, 1,7 Satoru Nagase, 2,7 Fumiaki Takahashi, 3 Kazuhiko
More informationRisk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department
More informationH&E, IHC anti- Cytokeratin
Cat No: OVC2281 - Ovary cancer tissue array Lot# Cores Size Cut Format QA/QC OVC228101 228 1.1mm 4um 12X19 H&E, IHC anti- Cytokeratin Recommended applications: For Research use only. RNA or protein ovary
More informationVulva Inflammatory Disorders Lichen Planus Fixed Drug Eruption Erythema Multiforme Plasmacytosis Mucosae (Zoon) Lichen Sclerosus Allergic Contact
Vulva Inflammatory Disorders Lichen Planus Fixed Drug Eruption Erythema Multiforme Plasmacytosis Mucosae (Zoon) Lichen Sclerosus Allergic Contact Dermatitis Psoriasis Lichen Simplex Chronicus Foreign Body
More informationICD-O Morphology code. R=Rare Tier Tumour ICD-O Topography code C30.0, C31
R=Rare Tier Tumour ICD-O Topography code ICD-O Morphology code EPITHELIAL TUMOURS OF NASAL CAVITY AND SINUSES R 2 Squamous cell carcinoma with variants of nasal cavity and sinuses C30.0, C3 C30.0, C3 8000,
More information3 cell types in the normal ovary
Ovarian tumors 3 cell types in the normal ovary Surface (coelomic epithelium) the origin of the great majority of ovarian tumors 90% of malignant ovarian tumors Totipotent germ cells Sex cord-stromal cells
More informationSpringer Healthcare. Understanding and Diagnosing Ovarian Cancer. Concise Reference: Krishnansu S Tewari, Bradley J Monk
Concise Reference: Understanding and Diagnosing Ovarian Cancer Krishnansu S Tewari, Bradley J Monk Extracted from: The 21 st Century Handbook of Clinical Ovarian Cancer Published by Springer Healthcare
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationEffective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific /N 8551/3 Acinar adenocarcinoma (C34. _) Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3
More information2018 ICD-O-3 Updates in Table Format with Annotation for Reference
Status Histology Description (this may be preferred term or a synonym) Report Comments New term 8010 3 Urachal carcinoma (C65.9, C66.9, C67._, C68._) New term 8013 3 Combined large cell neuroendocrine
More informationEffective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific Status /N 8010/3 Urachal carcinoma (C65.9, C66.9, C67. _, C68._) 8013/3 Combined large cell neuroendocrine carcinoma (C34. _, C37.9)
More informationGynecologic Malignancies. Kristen D Starbuck 4/20/18
Gynecologic Malignancies Kristen D Starbuck 4/20/18 Outline Female Cancer Statistics Uterine Cancer Adnexal Cancer Cervical Cancer Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial
More informationGynaecological Malignancies
Gynaecological Malignancies Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea Division of Pathology School of Medicine & Health Sciences Overview Genital tract tumors
More informationL/O/G/O. Ovarian Tumor. Xiaoyu Niu Obstetrics and Gynecology Department Sichuan University West China Second Hospital
L/O/G/O Ovarian Tumor Xiaoyu Niu Obstetrics and Gynecology Department Sichuan University West China Second Hospital Essentials classification of ovarian tumor clinical manifestation of ovarian tumor metastatic
More informationC ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
CLINICAL C ORPUS UTERI C ARCINOMA STAGING FORM PATHOLOGIC Extent of disease before S TAGE C ATEGORY D EFINITIONS Extent of disease through any treatment completion of definitive surgery y clinical staging
More informationDr Sanjiv Manek Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust
Dr Sanjiv Manek Oxford Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust Ovarian Endometrial Vulvo-vaginal Cervical Illustration-Cellular Pathology. Oxford
More informationType I. Type II. Excess estrogen Lynch Endometrioid adenocarcinoma PTEN. High grade More aggressive Serous, Clear Cell p53
Type I Excess estrogen Lynch Endometrioid adenocarcinoma PTEN Type II High grade More aggressive Serous, Clear Cell p53 Stage I IA IB Stage II Stage III IIIA IIIB IIIC IIIC1 IIIC2 Stage IV IVA IVB nodes
More informationVULVAR CARCINOMA. Page 1 of 5
VULVAR CARCINOMA EXAMPLE OF A VULVAR CARCINOMA USING PROPOSED TEMPLATE Case: Invasive squamous cell carcinoma arising in D-VIN Tumor in left labia major Left partial vaginectomy and sentinel lymph node
More informationHISTOLOGICAL TYPES OF UTERINE CANCER IN THE DR. SALVATOR VUIA CLINICAL OBSTETRICS AND GYNECOLOGY HOSPITAL ARAD DURING THE PERIOD
HISTOLOGICAL TYPES OF UTERINE CANCER IN THE DR. SALVATOR VUIA CLINICAL OBSTETRICS AND GYNECOLOGY HOSPITAL ARAD DURING THE 2000-2009 PERIOD Gheorghe Furău 1), Voicu Daşcău 1), Cristian Furău 1), Lucian
More information3 cell types in the normal ovary
Ovarian tumors 3 cell types in the normal ovary Surface (coelomic epithelium) the origin of the great majority of ovarian tumors (neoplasms) 90% of malignant ovarian tumors Totipotent germ cells Sex cord-stromal
More informationPathology of Ovarian Tumours. Dr. Jyothi Ranganathan MD ( Path) AFMC Pune PDCC (Cytopathology) PGI Chandigarh
Pathology of Ovarian Tumours Dr. Jyothi Ranganathan MD ( Path) AFMC Pune PDCC (Cytopathology) PGI Chandigarh Outline Incidence Risk factors Classification Pathology of tumours Tumour markers Prevention
More informationNew Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%
Uterine Malignancy New Cancer Cases By Site 2010 Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Cancer Deaths By Site 2010 Lung 26% Breast 15% Colo-Rectal 9% Pancreas 7%
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More information3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates
J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates Signs
More informationInstitute of Pathology First Faculty of Medicine Charles University. Ovary
Ovary Barrett esophagus ph in vagina between 3.8 and 4.5 ph of stomach varies from 1-2 (hydrochloric acid) up to 4-5 BE probably results from upward migration of columnar cells from gastroesophageal junction
More informationAppendix 4: WHO Classification of Tumours of the pancreas 17
S3.01 The WHO histological tumour type must be recorded. CS3.01a The histological type of the tumour should be recorded based on the current WHO classification 17 (refer to Appendices 4-7). Appendix 4:
More informationAdenocarcinoma of the Cervix
Question 1. Each of the following statements about cervical adenocarcinoma is true except: Adenocarcinoma of the Cervix SAMS a) A majority of women with cervical adenocarcinoma have stage I tumors at diagnosis.
More informationUterine Malignancies. Collecting Cancer Data: Uterine Malignancies 10/7/2010. NAACCR Webinar Series 1. Questions. Fabulous Prizes!!!
Uterine October 7, 2010 NAACCR 2010-2011 Webinar Series Session 1 1 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes!!! 3 NAACCR 2010-2011 Webinar
More informationAnalysis of Prognosis and Prognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix
DOI 10.1007/s11805-009-0133-8 133 Analysis of rognosis and rognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix Guangwen Yuan Lingying Wu Xiaoguang Li Manni Huang Department
More informationOvarian Tumors: A Study of 2146 Cases at AFIP, Rawalpindi, Pakistan.
Ovarian Tumors: A Study of 2146 Cases at AFIP, Rawalpindi, Pakistan. 1 Muhammad Zubair, 2 Shoaib Naiyar Hashmi, 3 Saeed Afzal, 4 Iqbal Muhammad, 5 Hafeez Ud Din, 6 Syed Naeem Raza Hamdani, 7 Rabia Ahmad.
More informationIndex. Cytoplasm, nonepithelial malignant tumor features 70
Accurette device 23 Adenosarcoma, differential diagnosis 80, 81 Arias-Stella reaction 65 Atypical endocervical cells 8 Atypical endometrial cells 8 Atypical glandular cells (AGC) 8, 9 Atypical glandular
More informationOVARIES. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L13 Dr: Ali Eltayb.
OVARIES MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L13 Dr: Ali Eltayb. OBJECTIVES Recognize different disease of ovaries Classify ovarian cyst Describe the pathogenesis, morphology
More informationAtypical Hyperplasia/EIN
EIN Atypical Hyperplasia/EIN Based on scientific and diagnostic advances, in 2014 the WHO moved that the precursor lesion for endometrioid carcinoma be atypical hyperplasia/ein, rather than what was previously
More informationUterine Cervix. Protocol applies to all invasive carcinomas of the cervix.
Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying
More informationGynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer
Gynecologic Oncology Pre invasive vulvar, vaginal, & cervical disease Vulvar Cervical Endometrial Uterine Sarcoma Fallopian Tube Ovarian GTD Gynecologic Oncologist Surgery Chemotherapy Radiation Therapy
More information2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:
E-Path A.I. Engine Knowledge Base Enhancements Version 1.0.0.29 April 1, 2018 The major enhancements in the E-Path Knowledge Base from versions 1.0.0.28 through 1.0.0.29 are as follows: 1. Addition/modification
More informationSee the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done.
About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. What Is
More informationUTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS
Review Journal of Translational Medicine and Research, volume 19, no. 1-2, 2014 UTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS N. Bacalbaæa 1, A. Traistaru 2, I. Bãlescu 3 1 Carol Davila University of Medicine
More informationCytology and Surgical Pathology of Gynecologic Neoplasms
Cytology and Surgical Pathology of Gynecologic Neoplasms Current Clinical Pathology ANTONIO GIORDANO, MD, PHD SERIES EDITOR For further titles published in this series, go to http://www.springer.com/springer/series/7632
More informationS2199 S2200. * Speaker's diagnosis 78
98 21 2 14 13:30 * Speaker's diagnosis 78 S2199 Meningioma 48 Papillary meningioma * 30 Angiomatous meningioma 15 Ependymoma 12 Papillary ependymoma 6 Anaplastic ependymoma 2 Cellular ependymoma 1 Hemangioblastoma
More informationPathology of the female genital tract
Pathology of the female genital tract Common illnesses of the female genital tract Before menarche Developmental anomalies Tumors (ovarial teratoma) Amenorrhea Fertile years PCOS, ovarian cysts Endometriosis
More informationFINALIZED SEER SINQ QUESTIONS
0076 Source 1: WHO Class CNS Tumors pgs: 33 MP/H Rules/Histology--Brain and CNS: What is the histology code for a tumor originating in the cerebellum and extending into the fourth ventricle described as
More informationAn Abnormal Cervicovaginal Cytology Smear in Uterine Carcinosarcoma Is an Adverse Prognostic Sign Analysis of 25 Cases
Anatomic Pathology / CYTOLOGY OF CARCINOSARCOMA OF UTERUS An Abnormal Cervicovaginal Cytology Smear in Uterine Carcinosarcoma Is an Adverse Prognostic Sign Analysis of 25 Cases Matthew J. Snyder, MD, 1
More informationDiagnostic accuracy of ultrasonography with color doppler imaging techniques in adnexal masses and correlation with histopathological analysis
Original Article Diagnostic accuracy of ultrasonography with color doppler imaging techniques in adnexal masses and correlation with histopathological analysis Neha Gupta 1*, Poonam Gupta 2, Omvati Gupta
More informationFemale Reproduc.ve System. Kris.ne Kra7s, M.D.
Female Reproduc.ve System Kris.ne Kra7s, M.D. Female Reproduc.ve System Outline Cervix Uterus Ovaries Breast Cervical Carcinoma Once the most common cancer in women now not even in top 10. Decrease due
More information2/9/2015. Bartholin Cyst. Vulva: Squamous epithelium skin. Vagina: Squamous epithelium mucosa. Cervix: Ectocervix: squamous Endocervix: glandular
Vulva: Squamous epithelium skin Bartholin Cyst Vagina: Squamous epithelium mucosa Cervix: Ectocervix: squamous Endocervix: glandular Slide courtesy of Dr. Lodge Rigal Slide courtesy of Dr. Lodge Rigal
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationFemale Reproduc.ve System. Kris.ne Kra7s, M.D.
Female Reproduc.ve System Kris.ne Kra7s, M.D. Female Reproduc.ve System Outline Cervix Uterus Ovaries Breast Female Reproduc.ve System Outline Cervix Cervical carcinoma Cervical Carcinoma Once the most
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More informationHow to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationCarcinoma of the Fallopian Tube
119 Carcinoma of the Fallopian Tube APM HEINTZ, F ODICINO, P MAISONNEUVE, U BELLER, JL BENEDET, WT CREASMAN, HYS NGAN and S PECORELLI STAGING Anatomy Primary site The Fallopian tube extends from the posterior
More informationJournal of Rawalpindi Medical College (JRMC); 2016;20(4):
Original Article Morphological Profile of Ovarian Tumours Bilquis Begum, Iram Nadeem Rana, Nadeem Ikram Department of Pathology, Rawalpindi Medical College, Rawalpindi Abstract Background: To study the
More informationCurrent Concept in Ovarian Carcinoma: Pathology Perspectives
Current Concept in Ovarian Carcinoma: Pathology Perspectives Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine Current Concept in Ovarian
More informationNAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary
NAACCR 2011 2012 Webinar Series Collecting Cancer Data: Ovary Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationCHAPTER 4 Specific tumor sites (part 2)
CANCER REGISTRATION HANDBOOK CHAPTER 4 Specific tumor sites (part 2) Contents IV(2)-2 IV(2)-2 IV(2)-3 IV(2)-3 IV(2)-3 IV(2)-3 IV(2)-3 IV(2)-4 IV(2)-4 IV(2)-4 IV(2)-6 IV(2)-7 IV(2)-7 IV(2)-8 IV(2)-8 IV(2)-8
More informationOther Sites. Table 2 Continued. MPH Rules 11/8/07. NAACCR Webinar Series 1
MPH s 11/8/07 Other s 1 Table 2 Continued Use this two-page table to select combination histology codes. Compare the terms in the diagnosis to the terms in Columns 1 and 2. If the terms match, code the
More informationProtocol for the Examination of Lymphadenectomy Specimens From Patients With Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis
Protocol for the Examination of Specimens From Patients With Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis Version: Testis 4.0.1.1 Protocol Posting Date: February 2019 Accreditation Requirements
More informationInvited Re vie W. Molecular genetics of ovarian carcinomas. Histology and Histo pathology
Histol Histopathol (1 999) 14: 269-277 http://www.ehu.es/histol-histopathol Histology and Histo pathology Invited Re vie W Molecular genetics of ovarian carcinomas J. Diebold Pathological Institute, Ludwig-Maximilians-University
More informationEndometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines
Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Endometrial Cancer Emad R. Sagr, MBBS, FRCSC Consultant Gynecology Oncology Security forces Hospital, Riyadh Epidemiology
More informationCytological Features of Cervical Smears in Serous Adenocarcinoma of the Endometrium
Jpn J Clin Oncol 2003;33(12)636 641 Cytological Features of Cervical Smears in Serous Adenocarcinoma of the Endometrium Yukiharu Todo, Shinichirou Minobe, Kazuhira Okamoto, Mahito Takeda, Yasuhiko Ebina,
More informationAdenocarcinoma of the Endometrium: An Institutional Review
Pieter Baltens, 1580. Feast of St. George. From the collection of Dr. Gordon and Adele Gilbert of St. Petersburg, Florida. Adenocarcinoma of the Endometrium: An Institutional Review Denis Cavanagh, MD;
More informationof 20 to 80 and subsequently declines [2].
- - According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord
More informationNAACCR Webinar Series /7/17
COLLECTING CANCER DATA: UTERUS 2017 2018 NAACCR WEBINAR SERIES Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationSurvival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran
ORIGINAL ARTICLE Survival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran Katayoun Ziari, Ebrahim Soleymani, and
More informationStaging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
More informationCase 1. Gynaecology Case Presentation. Objectives. Disclosures 22/10/ year old female Clinical history: Assess right ovarian cyst
Gynaecology Case Presentation Organ Imaging 2016 University of Toronto Sarah Johnson 39 year old female Clinical history: Assess right ovarian cyst Clinically diagnosed endometriosis Started fertility
More informationStage 3 ovarian cancer survival rate
Search Stage 3 ovarian cancer survival rate 19-5-2017 If you've been diagnosed with ovarian cancer, it's natural to wonder about your prognosis. Learn about survival rates, outlook, and more. Take the
More informationThe clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population
Zhang et al. BMC Cancer (2019) 19:22 https://doi.org/10.1186/s12885-018-5147-2 RESEARCH ARTICLE Open Access The clinicopathological features and treatment modalities associated with survival of neuroendocrine
More informationuterine cancer endometrial cancer
2018 ICD-10-CM Diagnosis Code. Adenocarcinoma of endometrium ; Cancer of the. (mucous membrane that lines the endometrial cavity). ICD-10-CM C54.1 is grouped. Home ICD 9 Codes Endometrial Cancer ICD 9
More informationStage 3 ovarian cancer survival rate
Stage 3 ovarian cancer survival rate Gogamz Menu The latest ovarian cancer survival statistics for the UK for Health Professionals. See data for age, trends over time, stage at diagnosis and more. 5-8-2014
More informationUterus Malignancies /5/15
Collecting Cancer Data: Uterus 2014-2015 NAACCR Webinar Series February 5, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationInteractive Staging Bee
Interactive Staging Bee ROBIN BILLET, MA, CTR GA/SC REGIONAL CONFERENCE NOVEMBER 6, 2018? Clinical Staging includes any information obtained about the extent of cancer obtained before initiation of treatment
More informationRARE EPITHELIAL TUMOURS OF BREAST RARE EPITHELIAL TUMOURS OF CORPUS UTERI EPITHELIAL TUMOURS OF CERVIX UTERI
RARE TUMOURS OF THE FEMALE GENITAL SYSTEM 17% OF FEMALE GENITAL SYSTEM TUMOURS ARE RARE 3 093 553 RARE EPITHELIAL TUMOURS OF BREAST RARE EPITHELIAL TUMOURS OF CORPUS UTERI 6 7 % OF RARE TUMOURS OUT OF
More informationStudy of morphological patterns of ovarian neoplasms
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 79-08, p-issn: 79-086. Volume 0, Issue 6 (Sep.- Oct. 0), PP -6 Study of morphological patterns of ovarian neoplasms Dr. Vaddatti tejeswini
More informationENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationARRO Case: Early-stage Endometrial Cancer
ARRO Case: Early-stage Endometrial Cancer Ankit Modh, MD (PGY-4) Faculty Advisor: Mohamed A Elshaikh, MD Department of Radiation Oncology Henry Ford Cancer Institute Case Presentation 70 y/o African American
More informationEndometrial cancer in women 45 years of age or younger: A clinicopathological analysis
American Journal of Obstetrics and Gynecology (2005) 193, 1640 4 www.ajog.org Endometrial cancer in women 45 years of age or younger: A clinicopathological analysis Gilbert P. Pellerin, MD, Michael A.
More informationHistopathological analysis of neoplastic and non neoplastic lesions of ovary: A study of one hundred cases
Orginal Article Histopathological analysis of neoplastic and non neoplastic lesions of ovary: A study of one hundred cases 2 G Prathima, Srikanth Shastry 2 Consultant Pathologist, Image Diagnostics, Kadapa,
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1 trials currently open for patients with pheochromocytoma and/or paraganglima (from trials.gov) www.clinicaltrials.gov; Active PPGL trials Status Of Sunitinib In Patients With Recurrent
More information2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018
1 2018 Grade PEGGY ADAMO, RHIT, CTR ADAMOM@MAIL.NIH.GOV OCTOBER 11, 2018 2 Acknowledgements Donna Hansen, CCR Jennifer Ruhl, NCI SEER Introduction 3 Histologic Type vs. Grade Credit: Dr. Kay Washington
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationHitting the High Points Gynecologic Oncology Review
Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and
More informationPage # 1. Endometrium. Cellular Components. Anatomical Regions. Management of SIL Thomas C. Wright, Jr. Most common diseases:
Endometrium Pathology of the Endometrium Thomas C. Wright Columbia University, New York, NY Most common diseases: Abnormal uterine bleeding Inflammatory conditions Benign neoplasms Endometrial cancer Anatomical
More informationIncidence, Histological Types and Age at Presentation of Borderline and Malignant Ovarian Tumors at a Tertiary Institute in Nepal
NJOG 01 Jul-Dec; 18 ():11-16 Original Article Incidence, Histological Types and Age at Presentation of Borderline and Malignant Ovarian Tumors at a Tertiary Institute in Nepal Deptartment of Obstetrics
More informationClinicopathological and Histological Features of Ovarian Tumour- A Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 9 Ver. IX (September. 2017), PP 56-60 www.iosrjournals.org Clinicopathological and Histological
More informationSociety of Gynecologic Oncologists of the Philippine
Philippine Society of Oncologists, Inc. Rm. 803, North Tower, Cathedral Heights Building Complex, St. Luke's Medical Center, E. Rodriguez Sr. Ave., Quezon City, 1102 Philippines Telephone No: 723-0301
More informationGeorge Cernile Artificial Intelligence in Medicine Toronto, ON. Carol L. Kosary National Cancer Institute Rockville, MD
George Cernile Artificial Intelligence in Medicine Toronto, ON Carol L. Kosary National Cancer Institute Rockville, MD Using RCA A system to convert free text pathology reports into a database of discrete
More informationCervical cancer presentation
Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000
More informationCase 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno
Case 1 Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno SAMO Interdisciplinary Workshop on Gynecological Tumors Lucern, October
More informationENODMETRIAL CARCINOMA: SPECIAL & NOT SO SPECIAL VARIANTS
ENODMETRIAL CARCINOMA: SPECIAL & NOT SO SPECIAL VARIANTS Pacific Northwest Society of Pathologists Vancouver, B.C. September 26, 2015 Teri A. Longacre, M.D. longacre@stanford.edu Stanford University, Stanford,
More informationCASE 4 21/07/2017. Ectopic Prostatic Tissue in Cervix. Female 31. LLETZ for borderline nuclear abnormalities
Female 31 CASE 4 LLETZ for borderline nuclear abnormalities PSA Ectopic Prostatic Tissue in Cervix AJSP 2006;30;209-215 usually incidental microscopic finding usually in ectocervical stroma? developmental
More informationInteresting Cases in Gynecologic Pathology. Michael Ward, MD Surgical Pathology Fellow University of Utah Health Sciences Center Salt Lake City, UT
Interesting Cases in Gynecologic Pathology Michael Ward, MD Surgical Pathology Fellow University of Utah Health Sciences Center Salt Lake City, UT Case 1 History: 50 year old woman with a uterine mass
More informationGisela Dallenbach-Hellweg Magnus von Knebel Doeberitz Marcus J.Trunk Color Atlas of Histopathology of the Cervix Uteri
Gisela Dallenbach-Hellweg Magnus von Knebel Doeberitz Marcus J.Trunk Color Atlas of Histopathology of the Cervix Uteri Gisela Dallenbach-Hellweg Magnus von Knebel Doeberitz Marcus J.Trunk Color Atlas of
More informationNew Developments in Immunohistochemistry for Gynecologic Pathology
New Developments in Immunohistochemistry for Gynecologic Pathology Michael T. Deavers, M.D. Professor, Departments of Pathology and Gynecologic Oncology Immunohistochemistry in Gynecologic Pathology Majority
More informationDisclosure. Case. Mixed Tumors of the Uterine Corpus and Cervix. I have nothing to disclose
Mixed Tumors of the Uterine Corpus and Cervix Marisa R. Nucci, M.D. Division of Women s and Perinatal Pathology Department of Pathology Brigham and Women s Hospital Boston, MA UCSF Current Issues in Anatomic
More informationMody. AIS vs. Invasive Adenocarcinoma of the Cervix
Common Problems in Gynecologic Pathology Michael T. Deavers, M.D. Houston Methodist Hospital, Houston, Texas Common Problems in Gynecologic Pathology Adenocarcinoma in-situ (AIS) of the Cervix vs. Invasive
More informationNormal endometrium: A, proliferative. B, secretory.
Normal endometrium: A, proliferative. B, secretory. Nội mạc tử cung Nội mạc tử cung Cyclic changes in endometrium.. Approximate relationship of useful microscopic changes. Arias-Stella reaction in endometrial
More information